经心尖经导管二尖瓣置换术(Tendyne系统)单中心中期结果
技术成功率100%,30天死亡率3.3%,随访中位2.8年全因死亡率50%、心血管死亡率27%,功能分级改善但中期生存仍差。
要点
- 高危患者Tendyne TMVR技术成功率高,30天死亡率低。
- 中期随访全因死亡率达50%,心血管死亡率27%。
- 术后无中度以上二尖瓣反流,NYHA II级比例显著提高。
核心结论
- 在高危患者中,Tendyne装置TMVR的手术相关并发症和死亡率可接受,中期功能分级改善,但中期生存仍较差。
研究设计与样本
- 平均年龄74.6±7.1岁,平均EuroScore 2为7.7±3.8%。
主要发现
- 技术成功率100%,30天死亡率3.3%。
- 术后无MR>轻度,4例(13%)为轻度MR,平均跨瓣压差3.7±1.1 mmHg。
- 中位随访2.8年(IQR 2)时全因死亡率50%、心血管死亡率27%,无装置相关并发症(除1例细菌性心内膜炎经药物治疗)。
- 随访时无MR>轻度,平均跨瓣压差2.9±1.7 mmHg,装置成功率100%。
- 最新随访NYHA II级占94%,基线为43%(p < 0.001),但30%因急性心衰再住院。
关键数值与推荐
- MR严重者占90%,中度伴狭窄者占10%;57%患者为NYHA III-IV级,左室射血分数42±13%。
临床怎么用
- 对于外科高危的严重二尖瓣反流患者,Tendyne TMVR可作为替代选择,但需权衡中期生存仍较差及心衰再住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In high-risk patients, transcatheter mitral valve replacement (TMVR) is an alternative to surgery and transcatheter edge-to-edge repair (TEER). This study aims to evaluate the mid-term results of TMVR with the Tendyne System in a real-world population at a single center. METHODS: Between November 2018 and December 2023, all consecutive patients undergoing TMVR with the Tendyne System were included. The primary outcomes were overall and cardiovascular death. Secondary outcomes included the absence of mitral regurgitation (MR) >mild, improved functional status and device success, as defined by the Mitral Valve Academic Research Consortium criteria. RESULTS: Thirty patients were included. Mean age was 74.6±7.1 years, with a mean EuroScore 2 of 7.7±3.8%. MR was severe in 90% of cases and moderate with concomitant stenosis in 10%; 57% of patients were in NYHA class III-IV, and left ventricular ejection fraction was 42±13%. Technical success was 100%; 30-day mortality was 3.3%; there was no MR > mild; 4 (13%) patients had mild MR; and the mean transvalvular gradient was 3.7±1.1 mmHg. At a median follow-up of 2.8 (IQR 2) years, overall mortality was 50% and cardiovascular mortality was 27%, and we had no device-related complications, apart from one case of bacterial endocarditis that was medically treated. None of the patients presented MR >mild; the mean transvalvular gradient was 2.9±1.7 mmHg. At the latest follow-up, the device success rate was 100%, and NYHA class II was observed in 94% of patients, compared with 43% at baseline (p < 0.001); however, 30% have had a rehospitalization for acute heart failure during FU. CONCLUSIONS: In high-risk patients, TMVR with the Tendyne device is associated with acceptable procedure-related morbidity and mortality and leads to mid-term improvement in functional class; however, mid-term survival remains poor.
引用
- Besola L, Di Franco C, Giorgi F, et al. Transapical transcatheter mitral valve replacement with apical tethering system. Single-center mid-term results. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42671329. doi:10.1093/icvts/ivag194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。